Aripiprazole long-acting injection

Promising but more evidence needed

Nicholas A Keks, Judy Hope, Christine Culhane

Research output: Contribution to journalArticleOtherpeer-review

2 Citations (Scopus)

Abstract

Objective: Aripiprazole long acting injection (ALAI) is now available, and this paper aims to assist clinicians in deciding when to use ALAI. Conclusion: Aripiprazole is a partial dopamine agonist with low sedation, relatively favourable metabolic profile and a tendency to lower, rather than raise, prolactin. Available for over a decade, aripiprazole has been increasingly recognised by many clinicians as a useful option in the treatment of psychoses. ALAI is a suspension of crystalline aripiprazole in water which takes 5-7 days to reach steady state after an initial intramuscular injection. Monthly injections achieve steady state in four months. Studies have demonstrated that ALAI is effective in aripiprazoleresponsive patients. ALAI was generally well tolerated, but more prone to cause extrapyramidal side-effects than the oral form. ALAI has not been compared with other depots. Although the recommended starting dose is 400 mg, it is likely that there will be significant inter-individual dose variation. Dose optimisation in each patient will be necessary for best effectiveness and tolerability. ALAI is currently appropriate for aripiprazole-responsive patients who need a depot, but clinicians are likely to try ALAI in patients who have been on other depots, particularly in whom weight gain and hyperprolactinaemia have been problematic.

Original languageEnglish
Pages (from-to)368-370
Number of pages3
JournalAustralasian Psychiatry
Volume24
Issue number4
DOIs
Publication statusPublished - 23 Feb 2016

Keywords

  • Aripiprazole long-acting injection
  • Depots
  • Pharmacotherapy
  • Schizophrenia

Cite this

@article{30ad7b6b7d864593824086a4d6287ba8,
title = "Aripiprazole long-acting injection: Promising but more evidence needed",
abstract = "Objective: Aripiprazole long acting injection (ALAI) is now available, and this paper aims to assist clinicians in deciding when to use ALAI. Conclusion: Aripiprazole is a partial dopamine agonist with low sedation, relatively favourable metabolic profile and a tendency to lower, rather than raise, prolactin. Available for over a decade, aripiprazole has been increasingly recognised by many clinicians as a useful option in the treatment of psychoses. ALAI is a suspension of crystalline aripiprazole in water which takes 5-7 days to reach steady state after an initial intramuscular injection. Monthly injections achieve steady state in four months. Studies have demonstrated that ALAI is effective in aripiprazoleresponsive patients. ALAI was generally well tolerated, but more prone to cause extrapyramidal side-effects than the oral form. ALAI has not been compared with other depots. Although the recommended starting dose is 400 mg, it is likely that there will be significant inter-individual dose variation. Dose optimisation in each patient will be necessary for best effectiveness and tolerability. ALAI is currently appropriate for aripiprazole-responsive patients who need a depot, but clinicians are likely to try ALAI in patients who have been on other depots, particularly in whom weight gain and hyperprolactinaemia have been problematic.",
keywords = "Aripiprazole long-acting injection, Depots, Pharmacotherapy, Schizophrenia",
author = "Keks, {Nicholas A} and Judy Hope and Christine Culhane",
year = "2016",
month = "2",
day = "23",
doi = "10.1177/1039856216632399",
language = "English",
volume = "24",
pages = "368--370",
journal = "Australasian Psychiatry",
issn = "1039-8562",
publisher = "SAGE Publications Ltd",
number = "4",

}

Aripiprazole long-acting injection : Promising but more evidence needed. / Keks, Nicholas A; Hope, Judy; Culhane, Christine.

In: Australasian Psychiatry, Vol. 24, No. 4, 23.02.2016, p. 368-370.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Aripiprazole long-acting injection

T2 - Promising but more evidence needed

AU - Keks, Nicholas A

AU - Hope, Judy

AU - Culhane, Christine

PY - 2016/2/23

Y1 - 2016/2/23

N2 - Objective: Aripiprazole long acting injection (ALAI) is now available, and this paper aims to assist clinicians in deciding when to use ALAI. Conclusion: Aripiprazole is a partial dopamine agonist with low sedation, relatively favourable metabolic profile and a tendency to lower, rather than raise, prolactin. Available for over a decade, aripiprazole has been increasingly recognised by many clinicians as a useful option in the treatment of psychoses. ALAI is a suspension of crystalline aripiprazole in water which takes 5-7 days to reach steady state after an initial intramuscular injection. Monthly injections achieve steady state in four months. Studies have demonstrated that ALAI is effective in aripiprazoleresponsive patients. ALAI was generally well tolerated, but more prone to cause extrapyramidal side-effects than the oral form. ALAI has not been compared with other depots. Although the recommended starting dose is 400 mg, it is likely that there will be significant inter-individual dose variation. Dose optimisation in each patient will be necessary for best effectiveness and tolerability. ALAI is currently appropriate for aripiprazole-responsive patients who need a depot, but clinicians are likely to try ALAI in patients who have been on other depots, particularly in whom weight gain and hyperprolactinaemia have been problematic.

AB - Objective: Aripiprazole long acting injection (ALAI) is now available, and this paper aims to assist clinicians in deciding when to use ALAI. Conclusion: Aripiprazole is a partial dopamine agonist with low sedation, relatively favourable metabolic profile and a tendency to lower, rather than raise, prolactin. Available for over a decade, aripiprazole has been increasingly recognised by many clinicians as a useful option in the treatment of psychoses. ALAI is a suspension of crystalline aripiprazole in water which takes 5-7 days to reach steady state after an initial intramuscular injection. Monthly injections achieve steady state in four months. Studies have demonstrated that ALAI is effective in aripiprazoleresponsive patients. ALAI was generally well tolerated, but more prone to cause extrapyramidal side-effects than the oral form. ALAI has not been compared with other depots. Although the recommended starting dose is 400 mg, it is likely that there will be significant inter-individual dose variation. Dose optimisation in each patient will be necessary for best effectiveness and tolerability. ALAI is currently appropriate for aripiprazole-responsive patients who need a depot, but clinicians are likely to try ALAI in patients who have been on other depots, particularly in whom weight gain and hyperprolactinaemia have been problematic.

KW - Aripiprazole long-acting injection

KW - Depots

KW - Pharmacotherapy

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84986557911&partnerID=8YFLogxK

U2 - 10.1177/1039856216632399

DO - 10.1177/1039856216632399

M3 - Article

VL - 24

SP - 368

EP - 370

JO - Australasian Psychiatry

JF - Australasian Psychiatry

SN - 1039-8562

IS - 4

ER -